Wire · opportunities
New FDA-cleared AI tool could help predict if breast cancer will return
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
The FDA has cleared TumorSight Risk, an AI tool developed by SimBioSys with NVIDIA technology, that predicts breast cancer recurrence risk prior to surgery using existing breast MRI, pathology, and clinical data. This tool aims to improve personalised treatment decisions for early-stage, hormone receptor-positive, HER2-negative breast cancer patients and is working toward insurance coverage.
This Wire brief sits within Fusion42's coverage of Digital Health, and 6 sources have reported it between 15 Oct 2026 and 17 Oct 2026.
◆ ◆ The Wire takeaway
You now have an AI-powered FDA-approved option to predict breast cancer return risk before surgery. If your startup offers diagnostic or treatment decision support, prepare to incorporate this data or risk losing ground in personalised cancer care.
◆ Coverage
6 sources · first reported 15 Oct 2026 · latest 17 Oct 2026
◆ Related on Wire
◆ Topics